Short Versus Long Antibiotic Course for Pleural Infection Management (SLIM Trial)
NCT04615286 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2021-12-21
Summary
Infection of the pleural space is serious condition that requires hospitalization, invasive interventions and long courses of antibiotics\[1\]. Treatment of pleural infection requires long hospital admission with a median of 19 days\[2\] and medical treatments fails requiring surgical intervention in up to 30% of cases\[3\]. The mortality from pleural infection is around 10% at 3 months\[4\].
Besides drainage of the infected fluid, antibiotics are a core component of management of pleural infection\[5\] and are typically given intravenously in the first few days of treatment until the condition is stabilized at which stage patients are shifted to oral antibiotics of equivalent spectrum. In almost half of the cases of pleural infection, the choice of antibiotics is entirely empirical due to low yield of microbiological tests on pleural fluid in these cases\[6\]. International guidelines cite a minimum length of antibiotic course of pleural infection of four weeks\[5,7\] with antibiotic courses typically lasting six weeks\[8\]. However, these recommendations are based on expert opinion with no robust evidence to support such durations.
The RAPID (renal function, age, purulence, infection source and dietary factors) score has recently been validated as a robust tool to predict 3-month mortality of patients with pleural infection based on demographic and laboratory data (table 1)\[4\]. A low score (0-2) is associated with 2-3% mortality, medium score (3-4) 9% mortality and high score (5-7) 30% mortality at three months\[9\]. The utility for this score in clinical management is yet to be determined and this study will attempt using this score to stratify lengths of antibiotic treatment based on proposed risk of adverse outcomes as stipulated by the RAPID score.
The aim of this study is to investigate the feasibility and safety of prescribing shorter courses of antibiotics (2-3 weeks) versus the standard longer courses (4-6 weeks) in medically-treated patients with pleural infection at lower risk of mortality (RAPID score 0-4) who can be safely discharged home within 14 days of hospitalization and how this impacts success of medical treatment.
Conditions
- Pleural Infection
Interventions
- OTHER
-
Short course (2-3 weeks) of antibiotics
Shorter course of antibiotic than standard care of 4-6 weeks
- OTHER
-
Standard (long course) of antibiotics
4-6 weeks of antibiotics
Sponsors & Collaborators
-
Alexandria University
lead OTHER
Principal Investigators
-
Maged Hassan, PhD · Alexandria University Faculty of Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-28
- Primary Completion
- 2021-11-10
- Completion
- 2021-12-06
Countries
- Egypt
Study Locations
More Related Trials
-
Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
NCT01723644 ·Status: COMPLETED ·Phase: NA
-
Supportive Treatment and Antibiotics for Mild Pediatric Pneumonia
NCT05726253 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
NCT07327619 ·Status: RECRUITING ·Phase: PHASE3
-
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
NCT07164131 ·Status: RECRUITING ·Phase: PHASE4
-
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
NCT00080496 ·Status: COMPLETED ·Phase: PHASE3
-
Duration of Antibiotic Therapy in Community - Acquired Pneumonia
NCT01492387 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU
NCT00307099 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
NCT01420744 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT04682899 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of Current Practice of Antimicrobial Use and Clinical Outcome in the Management of Pneumonia Among Pediatric Patients Admitted to Jimma Medical Center, Southwest Ethiopia: A Prospective Observational Study
NCT06830915 ·Status: COMPLETED
-
Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia
NCT00273676 ·Status: COMPLETED ·Phase: PHASE4
-
Antibiotic Therapy In Respiratory Tract Infections
NCT04166110 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Impact of a Regional Antimicrobial Stewardship on the Length of Stay of Patients Admitted to Hospital With Pneumonia
NCT02276092 ·Status: COMPLETED
-
Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia
NCT04724044 ·Status: COMPLETED ·Phase: PHASE3
-
The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
NCT00809328 ·Status: COMPLETED ·Phase: PHASE3
-
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
NCT05952648 ·Status: RECRUITING ·Phase: NA
-
Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
NCT07152587 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.
NCT04153682 ·Status: COMPLETED ·Phase: NA
-
Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs
NCT01532024 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
NCT01683487 ·Status: COMPLETED
-
Nutritional Assessment in Non-tuberculous Mycobacteria Pulmonary Disease
NCT05376280 ·Status: RECRUITING
-
Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia
NCT05568654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Ceftobiprole in Hospital Acquired Pneumonia
NCT00229008 ·Status: COMPLETED ·Phase: PHASE3
-
Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients
NCT04674410 ·Status: WITHDRAWN
-
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
NCT00111644 ·Status: COMPLETED ·Phase: PHASE2